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Abstract
Background: Evaluating patients with symptoms suggestive of acute coronary syndrome
(ACS) is a time consuming, expensive and problematic process in the emergency department.
This study aimed to evaluate the diagnostic and prognostic value of glycogen phosphorylase
isoenzyme-BB (GP-BB) in ACS.
Methods: A total of 72 patients (mean age 61.8 ± 11.6 years) with ACS were enrolled. The ELISA
method for determining GP-BB level was performed and considered positive at > 10 ng/mL.
Duration of angina, type of ACS, demographic features, myoglobin, creatinine kinase and
troponin T (cTnT) were also assessed. The cTnT levels eight hours after pain onset was
considered the gold standard test for the diagnosis of myocardial infarction.
Results: The most sensitive biomarker at first hour of admission was GP-BB (95.8%). How-
ever, the specificity of GP-BB was low (43.7%). Receiver operating characteristics curve analysis
of the GP-BB level for predicting myocardial infarction revealed the area under the curve value
as 0.82 (SE 0.04; 95% CI 0.78–0.85). Positive treadmill exercise test (60% vs 17%, p = 0.047),
coronary artery disease (CAD; 59% vs 19%, p = 0.007), percutaneous coronary intervention
(44% vs 27%, p = 0.031) and 30-day mortality and/or readmission (33% vs 5%, p = 0.028)
were found to be higher in unstable angina (UA) patients having GP-BB (+).
Conclusions: GP-BB is considerably cardiosensitive at the first hour of admission in pa-
tients with ACS, but the specificity of GP-BB is lower and it is elevated in nearly half of the
patients with UA. However, in this group, GP-BB predicts significant CAD and the combined
end-point of mortality and re-hospitalization. (Cardiol J 2011; 18, 5: 496–502)
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Introduction
Chest pain is one of the commonest complaints
among patients presenting to cardiology or emer-
gency departments. It may be the initial (and sole)
complaint of acute coronary syndrome (ACS) [1, 2].
Diagnosis of ACS is based on an assessment of risk
factors, careful and rapid assessment of ECG, and
measurement of cardiac enzymes [1, 3]. Cardiac
troponins, creatinine kinase isoenzyme MB (CK-
-MB) and myoglobin, which are routinely used in
the diagnosis of ACS, are not elevated in the initial
hours, removing their value in an early diagnosis
[1, 2].
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Human glycogen phosphorylase (GP), particu-
larly its isoenzyme BB (GP-BB), has a distinct sen-
sitivity to myocardial oxygen deficiency in car-
diomyocytes [4, 5]. There is evidence that GP-BB
is rapidly released into the circulation in the early
phase of ACS as well as after perioperative myo-
cardial infarction following coronary artery bypass
grafting (CABG) [6].
GP in mammals is known to have three major
isoenzymes: BB (brain), MM (muscle), and LL (liver).
GP-BB is also found in heart muscle, including hu-
man myocardium, where it is, besides the MM sub-
type, the predominant isoenzyme. Ischemia induces
glycogen breakdown. After changing from a struc-
turally bound form into a soluble cytosolic form
during phosphorolysis, the enzyme may penetrate
as a dimer through the altered cell membrane into
the extracellular space [5, 6]. This metabolic se-
quence reflects the strongly structural and functio-
nal coupling of GP-BB to the ischemia-sensitive
process of glycogenolysis [5, 6]. Therefore, the spe-
cific mechanism of GP-BB release suggests some
new aspects for the laboratory diagnosis of ACS.
In the present study, we aimed to (i) investi-
gate the diagnostic performance of first hour GP-
-BB in identifying different states of myocardial is-
chemia in patients with ACS; (ii) compare the diag-
nostic performance of first hour GP-BB to that of
serially measured myoglobin, CK-MB and cardiac
troponin T (cTnT); and (iii) determine the prognos-
tic value of GP-BB in patients with unstable angina
(UA) whose cTnT level was normal.
Methods
Study population
This prospective study was conducted in
80 patients admitted with a chief complaint of chest
pain to our emergency department. From the
80 patients initially entered into the study, eight were
later excluded (two because a diagnosis of ACS
could not be confirmed, and six because they were
lost from further follow-up). Inclusion criteria were:
patients presenting within two hours of symptom
onset and having typical chest pain. Patients were
excluded if they had renal insufficiency or any re-
nal disease impairing renal clearance, were < 18 ye-
ars of age, or had atypical chest pain. Patients were
also excluded who: had undergone percutaneous
transluminal coronary angioplasty or CABG within
the previous 30 days; had prior ACS within the pre-
vious 30 days; or had chronic muscle disease, pul-
monary thromboembolism or pericarditis.
The protocol of this study was approved by the
Local Ethics Committee, and written informed con-
sent was obtained from every participant in this
study.
All patients underwent a comprehensive inqui-
ry regarding the degree of angina pectoris, risk fac-
tors and past history. A complete blood count, bio-
chemical profile and an initial 12-lead ECG were
obtained. Subjects underwent serial ECG and car-
diac biomarkers follow-up every four hours. All
subjects were managed medically in conformity
with ACC/AHA ST elevation myocardial infarction
(STEMI), non-STEMI (NSTEMI) and UA guide-
lines [1–3]. All patients received treatment with p.o.
aspirin (300 mg), i.v. unfractionated heparin (bolus
of 60 U/kg bodyweight up to a maximum of 5,000 U
followed by continuous infusion of 7 U/kg per hour
titrated to an activated partial thromboplastin time
of 60–70 s), or 1 mg/kg enoxaparin subcutaneously
every 12 hours, and clopidogrel (loading dose of
300 mg followed by 75 mg daily). Fibrinolytic thera-
py was administered to STEMI patients, and they
underwent coronary angiography within five days.
NSTEMI patients and UA patients with high-risk
factors underwent coronary angiography within
24 hours. UA patients with low-risk factors initially
received medical therapy and were then directed
to the treadmill exercise stress test (TMET). If the
TMET was positive,  the patient was referred for
coronary angiography. Patients were re-evaluated
30 days later for mortality and/or readmission.
Definition of acute coronary syndrome
Patients with ACS were classified into the fol-
lowing:
1. STEMI: defined as having ST-segment elevation
≥ 1 mm in two contiguous leads (or ≥ 2 mm in
V1 to V3 leads) or new left bundle branch block
together with chest pain for > 30 min and/or
evidence of myonecrosis with elevated cTnT
level (> 0.1 ng/mL).
2. NSTEMI: defined as no ST-segment elevation
on ECG despite elevated cTnT level (> 0.1 ng/
/mL) and chest pain for more than 30 min.
3. UA: defined as ischemic chest pain lasting
more than 30 min with no evidence of myone-
crosis or ST elevation.
Coronary angiography and definition
of coronary artery disease
Selective coronary angiography was performed
in 32 (43%) patients under local anesthesia via the
femoral artery using the Judkins method [7]. All
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coronary angiograms were evaluated by two expe-
rienced cardiologists who were unaware of the labo-
ratory results of the patients. The severity of each
lesion was assessed by quantitative coronary an-
giography (QCA). Coronary artery disease (CAD)
was defined as ≥ 50% luminal diameter stenosis in
one or more major epicardial vessel. Ten (13.8%)
patients had previous coronary artery bypass sur-
gery. In these patients, CAD was defined as ≥ 50%
luminal diameter stenosis of a nongrafted major
coronary artery or 50% luminal diameter stenosis
of the vein or arterial bypass graft [8].
Biochemical and laboratory analysis
Levels of conventional cardiac markers, name-
ly myoglobin, CK-MB and cTnT, were measured by
in vitro quantitative electrochemiluminescence
immunoassay (ECLIA), sandwich test-specific an-
tibody system and myoglobin STAT (Short Turn-
Around Time), troponin STAT and CK-MB STAT
kits. Normal reference levels for myoglobin, CK-
-MB and cTnT were accepted as 0–72 ng/mL, 0.0–
–5.0 ng/mL and 0.0–0.1 ng/mL, respectively. At the
fourth, eighth and twelfth hours, repeat ECGs and
cardiac biomarker samples were obtained. For GP-
-BB measurements, 2.5 cc of venous blood was
drawn into EDTA-tubes. The tubes were centri-
fuged at 3,000 rpm for 7 min and plasma was stored
at –20°C. An ELISA for GP-BB was performed using
the Diacordon GP-BB (E-051) (DIAGENICS®) kit.
Levels of GP-BB were considered positive at values
exceeding 10 ng/mL [9]. The glomerular filtration
rates of the patients were calculated by the modifica-
tion of diet in renal disease formula [10], using age,
gender, serum creatinine, and ethnicity variables.
Statistical analysis
Distribution of data was assessed using one-
sample Kolmogorov-Smirnov test. Data was de-
monstrated as mean ± SD for normally distributed
continuous variables, median and interquartile
range (IQR) for skew-distributed continuous varia-
bles, and frequencies for categorical variables.
Groups were compared by ANOVA method or
c2 test. SPSS 15.0 statistical analysis software (SPSS
Inc., Chicago, IL, USA) was used to evaluate varia-
bles and tests. A p value < 0.05 was considered sig-
nificant. The eighth-hour cTnT level was accepted
as the gold standard for the diagnosis of myocardial
infarction. Cardiospecificity and sensitivity levels
for initial, fourth-hour and eighth-hour CK-MB and
myoglobin, and first-hour GP-BB levels, were cal-
culated according to the reference cardiosensitivi-
ty and specificity levels for eighth-hour cTnT level
by using the Pearson c2 test. Receiver operating
characteristics (ROC) curve analysis was performed
for the diagnostic value of GP-BB levels in ACS.
Results
Basal clinical characteristics
Of the 80 patients initially entered into the
study, eight were later excluded (two because a dia-
gnosis of ACS could not be confirmed, and six be-
cause they were lost from further follow-up). Se-
venty-two subjects were enrolled in the study. Fifty-
-four (75%) were male and the mean age was 62 ±
± 12 (range 37–85 years, median 61). Diabetes mel-
litus was present in 18 (25%) patients, and a histo-
ry of hypertension was present in 35 (49%). Thir-
ty-seven (51%) patients  had a history of smoking.
The mean time period between symptom on-
set and admission was 62 ± 22 (mean ± SD) minu-
tes (minimum 25 min, maximum 102 min). Among
all patients, 14 (19%) had a normal ECG on admis-
sion, 11 (15%) had an acute ST segment elevation,
18 (25%) had ST depression, 18 (25%) had T wave
inversion, seven (10%) had pathologic Q waves, and
four (6%) had any type of dysrhythmia. Sixty-three
patients complained of chest pain only, five patients
had both chest and back pain, two patients had chest
pain together with dyspnea, and two patients suf-
fered from chest pain, nausea and vomiting.
The final diagnosis of subjects was as follows:
48 (67%) had UA, 13 (18%) had NSTEMI, and 11
(15%) had STEMI (four anterior, four inferior, one
inferolateral, one inferior with right ventricular in-
volvement and one posterior myocardial infarction).
Biomarker levels and the number and percentage
of patients with elevated biomarkers in different
types of final diagnosis at first and fourth hours are
shown in Table 1.
GP-BB in patients with elevated cTnT
(NSTEMI or STEMI)
In the patients with NSTEMI, GP-BB was ele-
vated in all patients. Ten (91%) of 11 STEMI pa-
tients had an elevated GP-BB level at the first hour.
Using a cTnT level > 0.1 ng/mL at the eighth hour
as the gold standard for the diagnosis of acute myo-
cardial infarction (AMI), cardiosensitivity and car-
diospecificity values for myoglobin, CK-MB, cTnT
and GP-BB at the first and fourth hours were calcu-
lated. The results obtained are set out in Table 2.
The most sensitive biomarker of AMI at first hour
was GP-BB (95.8%). However, the specificity of
GP-BB for AMI was lowest when compared to oth-
er biomarkers (43.7%). ROC curve analysis re-
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vealed the area under the curve (AUC) value of the
GP-BB level in predicting myocardial infarction to
be 0.82 (SE 0.04; 95% CI 0.78–0.85) (Fig. 1).
GP-BB in patients with normal
eighth hour cTnT (UA)
Of the 48 patients with normal eighth hour
cTnT, 27 (56%) had elevated GP-BB levels on ad-
mission. GP-BB levels in UA patients (median 11.2,
IQR 2.1–21.2) were lower than in patients with
NSTEMI (median 61.3, IQR 35.1–78.4) and STEMI
(median 44.2, IQR 19.4–68.1), respectively (Fig. 2).
When patients with UA were further stratified into
two groups according to their GP-BB levels (≥ 10 ng/
/mL or < 10 ng/mL), positive treadmill exercise test
(60% vs 17%, p = 0.047), CAD (59% vs 19%, p =
= 0.007), percutaneous coronary intervention (44%
vs 27%, p = 0.031) and 30-day mortality and/or read-
mission (33% vs 5%, p = 0.028) were found to be high-
er in GP-BB (+) patients with UA (Table 3). As a fi-
nal diagnosis, non-cardiac chest pain (initially thought
to be ischemic) was present in 28 (33%) patients and
the negative predictive value of GP-BB (+) was 61%.
Discussion
The main findings of the present study are as
follows: (i) GP-BB was the most sensitive biomar-
Table 1. Biomarker levels and number and percentage of patients with elevated biomarkers in different
types of final diagnosis at first and fourth hours.
UA NSTEMI STEMI Patients with
elevated biomarker
Myoglobin
First hour level [ng/mL] 30.3 (20.1–76.4) 170.3 (45.1–312.4) 178.1 (75.1–378.4) 21 (29%)
median (IQR)
Fourth hour level [ng/mL] 34.3 (26.3–115.4) 234.3 (78.3–413.2) 314.2 (126.3–594.1) 26 (36%)
median (IQR)
CK-MB
First hour level [ng/mL] 3.1 (2.1–4.7) 9.2 (5.7–32.3) 13.2 (7.9–42.9) 17 (24%)
median (IQR)
Fourth hour level [ng/mL] 3.4 (2.1–5.1) 35.2 (8.7–112.3) 95.4 (18.7–172.1) 25 (35%)
median (IQR)
Troponin-T
First hour level [ng/mL] < 0.01 0.50 (0.11–0.89) 0.82 (0.54–1.1) 13 (18%)
median (IQR)
Fourth hour level [ng/mL] < 0.01 1.29 (0.27–2.31) 3.02 (0.93–5.11) 24 (33%)
median (IQR)
GP-BB
First hour level [ng/mL] 11.2 (2.1–21.2) 61.3 (35.1–78.4) 44.2 (19.4–68.1) 50 (69%)
median (IQR)
Fourth hour level [ng/mL] – – – –
median (IQR)
CK-MB — creatinine kinase isoenzyme MB; IQR — inter-quartile range; GP-BB — glycogen phosphorylase isoenzyme BB; NSTEMI — non-ST eleva-
tion myocardial infarction; STEMI — ST elevation myocardial infarction; UA — unstable angina
Table 2. Sensitivity and specificity of cardiac biomarkers for diagnosis of myocardial infarction at first
and fourth hours.
Sensitivity Specificity
First hour Fourth hour First hour Fourth hour
Myoglobin (%) 70.8 87.5 91.6 89.6
CK-MB (%) 62.5 95.8 95.8 95.7
Troponin-T (%) 54.1 100 100 100
GP-BB (%) 95.8* NA 43.7* NA
NA — not assessed; CK-MB — creatinine kinase isoenzyme MB; GP-BB — glycogen phosphorylase isoenzyme BB; *p < 0.001 for GP-BB vs other groups
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ker to detect myocardial infarction when compared
to myoglobin, CK-MB, and cTnT at first hour;
(ii) the specificity of GP-BB was the lowest and it
was found to be elevated in nearly half of the patients
with UA; (iii) UA patients with higher GP-BB le-
vels had higher frequency of CAD and a poorer prog-
nosis than those with a normal first hour GP-BB
level.
Figure 2. Comparison of glycogen phosphorylase iso-
enzyme-BB (GB-BB) levels in different groups of acute
coronary syndrome; UA — unstable angina; NSTEMI
— non-ST elevation myocardial infarction; STEMI —
ST elevation myocardial infarction
Figure 1. Receiver operating characteristics curve ana-
lysis for glycogen phosphorylase isoenzyme-BB level in
predicting acute myocardial infarction; AUC — area un-
der the curve; SE — standard error; CI — confidence
interval.
Table 3. Comparison of clinical characteristics and prognostic factors between GP-BB (+) and GP-BB (–)
patients with unstable angina.
GP-BB (+) GP-BB (–) P
(≥ 10 ng/mL), n = 27  (< 10 ng/mL), n = 21
Age (years) 61.9 ± 12.1 60.8 ± 12.4 NS
Male gender 20 (74%) 16 (76%) NS
Smoking 13 (48%) 10 (47%) NS
Hypertension 14 (51%) 11 (52%) NS
Diabetes mellitus 6 (22%) 6 (28%) NS
GFR (MDRD formula) [mL/min] 79.2 ± 16.1 78.1 ± 19.7 NS
ST-T alterations on ECG 20 (74%) 14 (67%) NS
Coronary angiography: 21 (78%) 11 (52%) NS
Performed initially 12 (44%) 9 (42%) NS
Performed because of positive TMET 9 (60%) 2 (17%) 0.047
Coronary artery disease (% of group) 16 (59%) 4 (19%) 0.007
PCI (% of group) 12 (44%) 3 (27%) 0.031
CABG (% of group) 4 (15%) 1 (9%) NS
30-day mortality and/or readmission: 9 (33%) 1 (5%) 0.028
30-day mortality 2 (7%) 0 (0%) NS
30-day readmission 7 (26%) 1 (5%) NS
GFR — glomerular filtration rate; MDRD — modification of diet in renal disease; ECG — electrocardiogram; TMET — treadmill exercise test;
PCI — percutaneous coronary intervention; CABG — coronary artery bypass grafting
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Glycogen phosphorylase (glycogen phosphory-
lase;-1.4-D-glucan: orthophosphate D-glucosyl-
transferase; GP-BB) is a glycolytic enzyme that
plays an essential role in the regulation of carbohy-
drate metabolism [11, 12]. It catalyzes the first step
of glycogenolysis, in which glycogen is converted
to glucose 1-phosphate (it mobilizes glycogen,
which is connected to the delivery of glucose) [11,
12]. These conditions appear during ischemia and
hypoglycemia. GP-BB is connected to glycogen in
a macromolecular complex that is structurally
bound to the sarcoplasmic reticulum (the sarcoplas-
mic reticulum glycogenolysis complex) [13, 14].
The degree of GP-BB association with this complex
depends above all on the metabolic state of the in-
dividual. During hypoxia, bounded GP-BB dissoci-
ates and turns to a soluble form of GP-BB which
can easily escape from the cell through diffusion [13,
14]. The early release of GP-BB into the blood is
a common result of the combination of escalated gly-
cogenolysis and increased permeability of cell mem-
branes which is typical for myocardial ischemia and
necrosis [12–14].
Mair et al. [15] investigated the diagnostic va-
lue of GP-BB and other cardiac biomarkers obtained
immediately at presentation from 48 consecutive
patients with UA or temporary ST-T changes. They
demonstrated that a considerably higher proportion
of GP-BB levels turned positive in UA patients with
temporary ST-T changes in their ECG compared to
other markers. There are studies showing an ele-
vation of GP-BB in the first 1–4 hours after ACS
[5, 16, 17]. It has also been shown that if early re-
perfusion was established in patients, GP-BB would
rise even earlier [5]. In a studyby Rabitzsch et al.
[17] in 27 patients with myocardial infarction, GP-
-BB levels were measured during the first ten hours
every hour, and thereafter every eight hours. Addi-
tionally, GP-BB levels were monitored after reper-
fusion was obtained through fibrinolytic treatment
of the patients. They reported that in patients with
AMI, GP-BB was the most sensitive cardiac marker
from the initiation of chest pain to the first four hours,
compared to myoglobin, CK-MB and cTnT [17].
Peetz et al. [11] investigated GP-BB in the early di-
agnosis of myocardial injury. A total of 61 patients
admitted to the emergency department with ACS
were tested for other cardiac biomarkers (CK-MB,
myoglobin, and cTnT) as well as GP-BB. It was dem-
onstrated that in patients with STEMI at the first
hour, both the sensitivity of GP-BB (100%) and the
specificity (96%) were highest. In UA/NSTEMI pa-
tients, a very high rate of elevated GP-BB was ob-
served (94% at three hours) compared to myoglo-
bin (67%), CK-MB (55.0%) and cTnT (33.8%) [11].
Our study found that GP-BB was the most sen-
sitive biomarker to detect myocardial infarction
when compared to myoglobin, CK-MB, and cTnT
at the first hour. This result is consistent with the
literature. However, the low specificity of GP-BB
is a major concern, and it was found to be elevated
in nearly half of the patients with UA. Such low
specificity agrees with previous studies: the reason
is the high levels of GP-BB in patients with UA. To
date, no study has been published on the prognos-
tic value of GP-BB. In this study, we attempted to
establish whether or not there is a relationship be-
tween GP-BB and short-term prognosis, by follow-
ing patients for one month. We found that UA pa-
tients with higher GP-BB levels had higher frequen-
cy of CAD and a worse prognosis than those with
normal first hour GP-BB level.
Limitations of the study
The major limitations of the present study are
the relatively small number of patients and that the
results are based on a single center. Because the study
population was highly selected, there was a higher
probability of ACS, which might improve the diagnos-
tic properties of biomarkers, especially myoglobin.
GP-BB was measured only at the first hour of admis-
sion, and the follow-up time was relatively short. Car-
diac TnT was selected (rather than regular cTnI or
SENSITIVE troponin I — ‘ultra’ troponin) because of
availability. Defining CAD is another limitation, as
stenosis < 50% may be the etiology of UA and ACS.
Conclusions
GP-BB is considerably cardiosensitive at the
first hour of ACS, but the specificity of GP-BB is
lower and it is elevated in nearly half of the patients
with UA. However, in this group, GP-BB has an
important prognostic role. It predicts significant
CAD and the combined endpoint of mortality and
re-hospitalization. Further studies are needed with
a larger number of subjects to better understand
GP-BB’s short-term and long-term prognostic sig-
nificance for ACS.
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